Paraoxonase-1 and linoleic acid oxidation in familial hypercholesterolemia

Biochemical and Biophysical Research Communications

Volumn 333, Issue 3, 2005, Pages 787-793

  Van Himbergen, Thomas M ^a,b   Van Tits, Lambertus J H ^b   Hectors, Magda P C ^b   De Graaf, Jacqueline ^b   Roest, Mark ^a   Stalenhoef, Anton F H ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Familial hypercholesterolemia; Linoleic acid; Oxidation; Paraoxonase 1

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS;

ADULT; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL, LDL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LINOLEIC ACID; MALE; MIDDLE AGED; OXIDATION-REDUCTION;

EID: 20744456918     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.05.176     Document Type: Article

References (37)

1. R. Humbert, D.A. Adler, C.M. Disteche, C. Hassett, C.J. Omiecinski, and C.E. Furlong The molecular basis of the human serum paraoxonase activity polymorphism Nat. Genet. 3 1993 73 76
2. H.G. Davies, R.J. Richter, M. Keifer, C.A. Broomfield, J. Sowalla, and C.E. Furlong The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin Nat. Genet. 14 1996 334 336
3. S. Adkins, K.N. Gan, M. Mody, and B.N. La Du Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes Am. J. Hum. Genet. 52 1993 598 608
4. V.H. Brophy, R.L. Jampsa, J.B. Clendenning, L.A. McKinstry, G.P. Jarvik, and C.E. Furlong Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression Am. J. Hum. Genet. 68 2001 1428 1436
5. T. Kujiraoka, T. Oka, M. Ishihara, T. Egashira, T. Fujioka, E. Saito, S. Saito, N.E. Miller, and H. Hattori A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration J. Lipid Res. 41 2000 1358 1363
6. H.W. Eckerson, C.M. Wyte, and B.N. La Du The human serum paraoxonase/arylesterase polymorphism Am. J. Hum. Genet. 35 1983 1126 1138
7. D.M. Shih, L. Gu, Y.R. Xia, M. Navab, W.F. Li, S. Hama, L.W. Castellani, C.E. Furlong, L.G. Costa, A.M. Fogelman, and A.J. Lusis Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis Nature 394 1998 284 287
8. B. Mackness, P. Durrington, P. McElduff, J. Yarnell, N. Azam, M. Watt, and M. Mackness Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study Circulation 107 2003 2775 2779
9. D. Steinberg, S. Parthasarathy, T.E. Carew, J.C. Khoo, and J.L. Witztum Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity N. Engl. J. Med. 320 1989 915 924
10. M.I. Mackness, S. Arrol, and P.N. Durrington Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein FEBS Lett. 286 1991 152 154
11. A.D. Watson, J.A. Berliner, S.Y. Hama, B.N. La Du, K.F. Faull, A.M. Fogelman, and M. Navab Protective effect of high density lipoprotein-associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein J. Clin. Invest. 96 1995 2882 2891
12. O. Rozenberg, M. Rosenblat, R. Coleman, D.M. Shih, and M. Aviram Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice Free Radic. Biol. Med. 34 2003 774 784
13. A. Tward, Y.R. Xia, X.P. Wang, Y.S. Shi, C. Park, L.W. Castellani, A.J. Lusis, and D.M. Shih Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice Circulation 106 2002 484 490
14. A. Bub, S.W. Barth, B. Watzl, K. Briviba, and G. Rechkemmer Paraoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid peroxidation in healthy young men on a low-carotenoid diet supplemented with tomato juice Br. J. Nutr. 93 2005 291 297
15. T. Van Himbergen, M. Roest, F. De Waart, J. De Graaf, H. Voorbij, L. Van Tits, and A. Stalenhoef Paraoxonase genotype, LDL-oxidation and carotid atherosclerosis in male life-long smokers Free Radic. Res. 38 2004 553 560
16. M.J. Sampson, S. Astley, T. Richardson, G. Willis, I.R. Davies, D.A. Hughes, and S. Southon Increased DNA oxidative susceptibility without increased plasma LDL oxidizability in type II diabetes: effects of alpha-tocopherol supplementation Clin. Sci. (Lond) 101 2001 235 241
17. S. Tsuzura, Y. Ikeda, T. Suehiro, K. Ota, F. Osaki, K. Arii, Y. Kumon, and K. Hashimoto Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes Metabolism 53 2004 297 302
18. S. Kopprasch, J. Pietzsch, E. Kuhlisch, and J. Graessler Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus J. Clin. Endocrinol. Metab. 88 2003 1711 1716
19. M. Sampson, S. Braschi, G. Willis, and S. Astley Paraoxonase -1 (PON1) genotype and activity and in vivo oxidised plasma low density lipoprotein [oxLDL] in type 2 diabetes Clin. Sci. (Lond) 2005
20. T.M. van Himbergen, M. Roest, J. de Graaf, E.H. Jansen, H. Hattori, J.J. Kastelein, H.A. Voorbij, A.F. Stalenhoef, and L.J. van Tits Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia J. Lipid Res. 46 2005 445 451
21. R. Malin, S. Laine, V. Rantalaiho, O. Wirta, A. Pasternack, H. Jokela, H. Alho, T. Koivula, and T. Lehtimaki Lipid peroxidation is increased in paraoxonase L55 homozygotes compared with M-allele carriers Free Radic. Res. 34 2001 477 484
22. G. Spiteller Linoleic acid peroxidation-the dominant lipid peroxidation process in low density lipoprotein-and its relationship to chronic diseases Chem. Phys. Lipids 95 1998 105 162
23. P. Spiteller, and G. Spiteller 9-Hydroxy-10,12-octadecadienoic acid (9-HODE) and 13-hydroxy-9,11-octadecadienoic acid (13-HODE): excellent markers for lipid peroxidation Chem. Phys. Lipids 89 1997 131 139
24. T.J. Smilde, S. van Wissen, H. Wollersheim, M.D. Trip, J.J. Kastelein, and A.F. Stalenhoef Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial Lancet 357 2001 577 581
25. T.J. Smilde, H. Wollersheim, S. Van Wissen, J.J.P. Kastelein, and A.F.H. Stalenhoef Rationale, design and baseline characteristics of a clinical trial comparing the effects of robust vs conventional cholesterol lowering and intima media thickness in patients with familial hypercholesterolaemia: the atorvastatin versus simvastatin on atherosclerosis progression (ASAP) study Clin. Drug Invest. 20 2000 67 79
26. I. Leviev, and R.W. James Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations Arterioscler Thromb. Vasc. Biol. 20 2000 516 521
27. R.J. Richter, and C.E. Furlong Determination of paraoxonase (PON1) status requires more than genotyping Pharmacogenetics 9 1999 745 753
28. P.W. Connelly, D. Draganov, and G.F. Maguire Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite Free Radic. Biol. Med. 38 2005 164 174
29. J.F. Teiber, D.I. Draganov, and B.N. La Du Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH J. Lipid Res. 45 2004 2260 2268
30. G.K. Marathe, G.A. Zimmerman, and T.M. McIntyre Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles J. Biol. Chem. 278 2003 3937 3947
31. H. Esterbauer, J. Gebicki, H. Puhl, and G. Jurgens The role of lipid peroxidation and antioxidants in oxidative modification of LDL Free Radic. Biol. Med. 13 1992 341 390
32. L. Nagy, P. Tontonoz, J.G. Alvarez, H. Chen, and R.M. Evans Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma Cell 93 1998 229 240
33. G. Chinetti, S. Lestavel, V. Bocher, A.T. Remaley, B. Neve, I.P. Torra, E. Teissier, A. Minnich, M. Jaye, N. Duverger, H.B. Brewer, J.C. Fruchart, V. Clavey, and B. Staels PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway Nat. Med. 7 2001 53 58
34. A. Chawla, W.A. Boisvert, C.H. Lee, B.A. Laffitte, Y. Barak, S.B. Joseph, D. Liao, L. Nagy, P.A. Edwards, L.K. Curtiss, R.M. Evans, and P. Tontonoz A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis Mol. Cell 7 2001 161 171
35. M.J. van Dam, E. de Groot, S.M. Clee, G.K. Hovingh, R. Roelants, A. Brooks-Wilson, A.H. Zwinderman, A.J. Smit, A.H. Smelt, A.K. Groen, M.R. Hayden, and J.J. Kastelein Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study Lancet 359 2002 37 42
36. W.A. Harland, J.D. Gilbert, G. Steel, and C.J. Brooks Lipids of human atheroma 5. The occurrence of a new group of polar sterol esters in various stages of human atherosclerosis Atherosclerosis 13 1971 239 246
37. W. Jira, G. Spiteller, W. Carson, and A. Schramm Strong increase in hydroxy fatty acids derived from linoleic acid in human low density lipoproteins of atherosclerotic patients Chem. Phys. Lipids 91 1998 1 11